CovidVax show full list
COVID-19 VACCINE:

adenovirus based NasoVAX (intranasal)

researcher:
Altimmune + University of Alabama + DynPort Vaccine Company
https://altimmune.com/
(USA)
vaccine type: Non-replicating viral vector
Distribution updates
currently no distribution info
Human Testing updates (clinical trials)

PHASE 1

 

started February 2021

with 180 healthy volunteers aged 18-55

trial location: USA

» clinical trial details

Feb 25Altimmune single-dose intranasal COVID-19 vaccine has started its Phase 1 clinical trial with up to 180 healthy volunteers (by globenewswire.com)
Dec 23US FDA has issued a clinical hold on Altimmune's vaccine requesting protocol modifications and the submission of additional CMC data (by altimmune.com)
Nov 25Altimmune has submitted an IND application to US' FDA to commence a Phase 1 clinical study of its vaccine (by altimmune.com)
Feb 28Altimmune could begin clinical testing of its vaccine as early as August (by globenewswire.com)
Animal Testing updates (pre-clinical trials)
start date: April 2020
Oct 12Altimmune pre-published a comprehensive preclinical evaluation of its single dose intranasal vaccine candidate (by altimmune.com)
Mar 30UAB will test vaccine in mice before Altimmune can launch human trial in Q3 2020 (by uab.edu)
early development updates
Jul 09Altimmune signed an agreement with DynPort for the development of its vaccine (by globenewswire.com)



partnerships:
Mar 30Altimmune starts a partnership with the University of Alabama to develop intranasal vaccine (by altimmune.com)



contact | about | ©2020 CovidVax.org project